Downregulation of brca1 protein in bcr-abl1 leukemia cells depends on stress-triggered tiar-mediated suppression of translation

Cell Cycle

Volumn 13, Issue 23, 2014, Pages 3727-3741

  Podszywalow Bartnicka, Paulina ^a   Wolczyk, Magdalena ^a   Kusio Kobialka, Monika ^a   Wolanin, Kamila ^a,d   Skowronek, Krzysztof ^a,b   Nieborowska Skorska, Margaret ^c   Dasgupta, Yashodhara ^c   Skorski, Tomasz ^c   Piwocka, Katarzyna ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

BCR ABL; BRCA1; Cell cycle; Dna damage response; HuR; MRNA binding protein; Stress response; Synthetic lethality; TIAR; Translation

Indexed keywords

BCR ABL PROTEIN; BRCA1 PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; MESSENGER RNA; RNA BINDING PROTEIN; TIAL1 PROTEIN, MOUSE;

ANEUPLOIDY; ANIMAL CELL; ARTICLE; AU RICH ELEMENT; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; ENDOPLASMIC RETICULUM STRESS; GENOMIC INSTABILITY; LEUKEMIA CELL; NONHUMAN; PRIMARY CELL; PROTEIN DEGRADATION; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSLATION; WESTERN BLOTTING; ANIMAL; CHRONIC MYELOID LEUKEMIA; GENETICS; HUMAN; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ANIMALS; BRCA1 PROTEIN; CELL LINE, TUMOR; DOWN-REGULATION; ENDOPLASMIC RETICULUM STRESS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; PROTEIN BIOSYNTHESIS; RNA, MESSENGER; RNA-BINDING PROTEINS;

EID: 84920618238     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.965013     Document Type: Article

References (40)

1. Perrotti D, Neviani P. Unfolding tyrosine kinase inhibitor sensitivity in chronic myeloid leukemia. Cell Cycle 2012; 11:4300-1; PMID:23159861; http://dx.doi.org/ 10.4161/cc.22808
2. Penserga ET, Skorski T. Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene 2007; 26:11-20; PMID:16785987; http://dx.doi.org/ 10.1038/sj.onc.1209756
3. Deutsch E, Jarrousse S, Buet D, Dugray A, Bonnet ML, Vozenin-Brotons MC, Guilhot F, Turhan AG, Feunteun J, Bourhis J. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood 2003; 101:4583-88; PMID:12576338; http://dx.doi.org/ 10.1182/blood-2002-10-3011
4. Wolanin K, Magalska A, Kusio-Kobialka M, Podszy-walow-Bartnicka P, Vejda S, McKenna SL, Mosieniak G, Sikora E, Piwocka K. Expression of oncogenic kinase Bcr-Abl impairs mitotic checkpoint and promotes aberrant divisions and resistance to microtubuletargeting agents. Mol. Cancer. Ther 2010; 9:1328-38.
5. Piwocka K, Wolanin K, Kusio-Kobialka M, Podszywa-low-Bartnicka P. BCR-ABL Hits at Mitosis; Implications for Chromosomal Instability, Aneuploidy and Therapeutic Strategy. In: Myeloid Leukemia - Basic Mechanisms of Leukemogenesis, ed. S. Koschmieder, U. Krug. InTech Press 2011, p. 1-26.
6. Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, et al. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood 2013; 122:1293-304; PMID:23836560; http://dx.doi.org/ 10.1182/blood-2013-05-501072
7. Wu J, Lu LY, Yu X. The role of BRCA1 in DNA damage response. Protein Cell 2010; 1:117-23; PMID:21203981; http://dx.doi.org/10.1007/s13238-010-0010-5
8. Moiola C, De Luca P, Cotignola J, Gardner K, Vazquez E, De Siervi A. Dynamic Coregulatory Complex Containing BRCA1, E2F1 and CtIP Controls ATM Transcription. Cell Physiol. Biochem2012; 30:596-608
9. Friedenson B. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer 2007; 7:152; PMID:17683622; http://dx.doi.org/10.1186/1471-2407-7-152
10. Kusio-Kobialka M, Podszywalow-Bartnicka P, Peidis P, Glodkowska-Mrowka E, Wolanin K, Leszak G, Seferynska I, Stoklosa T, Koromilas AE, Piwocka K. The PERK-eIF2a phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells. Cell Cycle 2012; 11:4069-78; PMID:23095523; http://dx.doi.org/10.4161/cc.22387
11. Kedersha N, Anderson P. Stress granules: sites of mRNA triage that regulate mRNA stability and translatability. Biochem Soc Trans 2002; 30:963-9; PMID:12440955; http://dx.doi.org/10.1042/ BST0300963
12. Kedersha NL, Gupta M, Li W, Miller I, Anderson P. RNA-binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2 alpha to the assembly of mammalian stress granules. J Cell Biol 1999; 147:1431-42; PMID:10613902; http://dx.doi.org/10.1083/ jcb.147.7.1431
13. Nowicki MO, Pawlowski P, Fischer T, Hess G, Pawlowski T, Skorski T. Chronic myelogenous leukemia molecular signature. Oncogene 2003; 22:3952-63; PMID:12813469; http://dx.doi.org/10.1038/sj. onc.1206620
14. Caestecker KW, Van de Walle GR. The role of BRCA1 in DNA double-strand repair: past and present. Exp Cell Res 2013; 319:575-87; PMID:23200932; http:// dx.doi.org/10.1016/j.yexcr.2012.11.013
15. Trotta R, Vignudelli T, Candini O, Intine RV, Pecorari L, Guerzoni C, Santilli G, Byrom MW, Goldoni S, Ford LP, et al. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 2003; 3:145-60; PMID:12620409; http://dx.doi.org/ 10.1016/S1535-6108(03)00020-5
16. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. Global quantification of mammalian gene expression control. Nature 2011; 473:337-42; PMID:21593866; http://dx.doi. org/10.1038/nature10098
17. Guerzoni C, Bardini M, Mariani SA, Ferrari-Amorotti G, Neviani P, Panno ML, Zhang Y, Martinez R, Perrotti D, Calabretta B. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABLexpressing cells. Blood 2006; 107:4080-89; PMID:16418324; http://dx.doi.org/10.1182/blood-2005-08-3181
18. Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M, Willis W, Gambacorti-Passerini C, Volinia S, Marcucci G, et al. Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood 2008; 111:816-28; PMID:17925491; http://dx.doi.org/ 10.1182/blood-2007-05-090472
19. Saunus JM, Edwards SL, French JD, Smart CE, Brown MA. Regulation of BRCA1 messenger RNA stability in human epithelial cell lines and during cell cycle progression. FEBS Lett 2007; 581:3435-42; PMID:17612526; http://dx.doi.org/10.1016/j. febslet.2007.06.046
20. Saunus JM, French JD, Edwards SL, Beveridge DJ, Hatchell EC, Wagner SA, Stein SR, Davidson A, Simpson KJ, Francis GD, et al. Posttranscriptional regulation of the breast cancer susceptibility gene BRCA1 by the RNA binding protein HuR. Cancer Res 2008; 68:9469-78; PMID:19010922; http://dx.doi.org/ 10.1158/0008-5472.CAN-08-1159
21. Cok SJ, Acton SJ, Morrison AR. The proximal region of the 3'-untranslated region of cyclooxygenase-2 is recognized by a multimeric protein complex containing HuR, TIA-1, TIAR, and the heterogeneous nuclear ribonucleoprotein U. J Biol Chem 2003; 278:36157-62; PMID:12855701; http://dx.doi.org/10.1074/jbc. M302547200
22. Lu PD, Harding HP, Ron D. Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. J Cell Biol 2004 Oct 11; 167(1):27-33; http://dx.doi.org/ 10.1083/jcb.200408003
23. Wolanin K, Magalska A, Mosieniak G, Klinger R, McKenna S, Vejda S, Sikora E, Piwocka K. Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells. Mol Cancer Res 2006; 4:457-69; PMID:16849521; http://dx.doi.org/ 10.1158/1541-7786.MCR-05-0172
24. Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, Salgia R, Podar K, Griffin JD, Sattler M. Activation of the PI3K/mTOR pathway by BCRABL contributes to increased production of reactive oxygen species. Blood 2005; 105:1717-23; PMID:15486067; http://dx.doi.org/10.1182/blood-2004-03-0849
25. Prabhu S, Saadat D, Zhang M, Halbur L, Fruehauf JP, Ong ST. A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene 2007; 26:1188-200; PMID:16936779; http://dx.doi.org/ 10.1038/sj.onc.1209901
26. Schuster K, Zheng J, Arbini AA, Zhang CC, Scaglioni PP. Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo. Blood Cancer J 2011, 1:e34; PMID:22829195; http://dx.doi.org/10.1038/ bcj.2011.30
27. Lopez de Silanes I, Lal A, Gorospe M. HuR: post-transcriptional paths to malignancy. RNA Biol 2005; 2:11-13; PMID:17132932; http://dx.doi.org/10.4161/ rna.2.1.1552
28. Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomaki K, Blomqvist C, Heikkila P, Haglund C, Nevanlinna H, Ristimaki A. Prognostic role of HuR in hereditary breast cancer. Clin. Cancer Res 2007; 13:6959-63;
29. Liu Y, Yu W. Heat shock-mediated regulation of IkB- a at the post-transcriptional level by HuR. Mol Med Rep 2014; 9: 553-9; PMID:24271119
30. Buchan JR. mRNP granules: Assembly, function, and connections with disease. RNA Biol 2014, 11(8):[Epub ahead of print]; PMID:24866467; http://dx.doi.org/ 10.4161/rna.29034
31. Mazan-Mamczarz K, Lal A, Martindale JL, Kawai T, Gorospe M. Translational repression by RNA-binding protein TIAR. Mol Cell Biol 2006; 26:2716-27; PMID:16537914; http://dx.doi.org/10.1128/ MCB.26.7.2716-2727.2006
32. Anderson P, Kedersha N. Stressful initiations. J Cell Sci 2002; 115:3227-34; PMID:12140254
33. Gottschald OR, Malec V, Krasteva G, Hasan D, Kamlah F, Herold S, Rose F, Seeger W, Hanze J. TIAR and TIA-1 mRNA-binding proteins co-aggregate under conditions of rapid oxygen decline and extreme hypoxia and suppress the HIF-1a pathway. J Mol Cell Biol 2010; 2:345-56; PMID:20980400; http://dx.doi.org/ 10.1093/jmcb/mjq032
34. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010; 140:652-65; PMID:20211135; http:// dx.doi.org/10.1016/j.cell.2010.01.007
35. Fang B. 2014 Development of Synthetic Lethality Anticancer Therapeutics. J Med Chem 2014 Jun 13. [Epub ahead of print]
36. Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood 2012; 119:4253-63; PMID:22411871; http://dx.doi.org/ 10.1182/blood-2011-10-385658
37. Wang Q, Zhang H, Guerrette S, Chen J, Mazurek A, Wilson T, Slupianek A, Skorski T, Fishel R, Greene MI. Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1. Oncogene 2001; 20:4640-49; PMID:11498787; http://dx.doi.org/ 10.1038/sj.onc.1204625
38. Masuda K, Abdelmohsen K, Kim MM, Srikantan S, Lee EK, Tominaga K, Selimyan R, Martindale JL, Yang X, Lehrmann E, et al. Global dissociation of HuR-mRNA complexes promotes cell survival after ionizing radiation. EMBO J 2011; 30:1040-53; PMID:21317874; http:// dx.doi.org/10.1038/emboj.2011.24
39. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-8; PMID:11846609; http://dx.doi.org/ 10.1006/meth.2001.1262
40. Kong YW, Cannell IG, de Moor CH, Hill K, Garside PG, Hamilton TL, Meijer HA, Dobbyn HC, Stoneley M, Spriggs KA, et al. The mechanism of micro-RNAmediated translation repression is determined by the promoter of the target gene. Proc Natl Acad Sci USA 2008; 105:8866-71;PMID:18579786; http://dx.doi. org/10.1073/pnas.0800650105